Effects of HSP90 Inhibition on Cell Cycle in Cancer Cells
Author Information
Author(s): Lyman Susan K., Crawley Suzanne C., Gong Ruoyu, Adamkewicz Joanne I., McGrath Garth, Chew Jason Y., Choi Jennifer, Holst Charles R., Goon Leanne H., Detmer Scott A., Vaclavikova Jana, Gerritsen Mary E., Blake Robert A.
Primary Institution: Exelixis, Inc.
Hypothesis
The study investigates the correlation between cell genotype and cell cycle phenotypes induced by HSP90 inhibition.
Conclusion
HSP90 inhibition leads to distinct cell cycle responses that depend on the cellular genotype and treatment conditions.
Supporting Evidence
- HSP90 inhibition caused accumulation in M-phase, G2-phase, or G1-phase in cancer cells.
- M-phase arrest correlated with TP53 mutations.
- Cell cycle responses varied significantly based on the concentration of HSP90 inhibitors used.
Takeaway
This study looks at how a cancer drug affects the way cancer cells grow and divide, showing that different types of cancer cells react in different ways.
Methodology
A high-content, high-throughput cell cycle assay was developed to profile the effects of HSP90 inhibitors in a panel of cancer cell lines.
Potential Biases
Potential bias due to the focus on specific cancer cell lines and the inherent variability in cell line responses.
Limitations
The study is limited to a specific panel of cancer cell lines and may not represent all cancer types.
Participant Demographics
The study included a genetically diverse panel of 25 cancer cell lines from lung, breast, and melanoma origins.
Statistical Information
P-Value
0.0089
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website